MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives

@inproceedings{Aquino2017MRIIG,
  title={MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives},
  author={Domenico Aquino and Andrea Gioppo and Gaetano Finocchiaro and Maria Grazia Bruzzone and Valeria Cuccarini},
  booktitle={Journal of immunology research},
  year={2017}
}
Pseudophenomena, that is, imaging alterations due to therapy rather than tumor evolution, have an important impact on the management of glioma patients and the results of clinical trials. RANO (response assessment in neurooncology) criteria, including conventional MRI (cMRI), addressed the issues of pseudoprogression after radiotherapy and concomitant chemotherapy and pseudoresponse during antiangiogenic therapy of glioblastomas (GBM) and other gliomas. The development of cancer immunotherapy… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 126 REFERENCES

MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study

Matej Vrabec, Sofie Van Cauter, +5 authors Philippe Demaerel
  • Neuroradiology
  • 2010
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Magnetic resonance imaging of perfusion using spin inversion of arterial water.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 1992
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Di ff erentiating tumor progression from pseudoprogression in patients with glioblastomas using di ff usion tensor imaging and dynamic susceptibility contrast MRI

H. Tan, J. Zhang, W. Zhao, M. D. Chan, X. Zhou
  • AJNR . American Journal of Neuroradiology
  • 2016